Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5440552 | 0.94 | MAOB (0.42) | MAOBSIGMAR1MAOAMAPTRXFP1 | |
| SCHEMBL5246710 | 0.82 | MAPT (0.43) | MAOBSIGMAR1MAOAMAPTRXFP1 | |
| SCHEMBL3822512 | 0.81 | SIGMAR1 (0.38) | MAOBSIGMAR1MAOA | |
| SCHEMBL8496868 | 0.72 | SIGMAR1 (0.58) | MAOBSIGMAR1MAOAMAPTRXFP1 | |
| SCHEMBL145792 | 0.72 | SIGMAR1 (0.58) | MAOBSIGMAR1MAOAMAPTRXFP1 | |
| SCHEMBL304117 | 0.72 | SIGMAR1 (0.58) | MAOBSIGMAR1MAOAMAPTRXFP1 | |
| SCHEMBL104035 | 0.72 | SIGMAR1 (0.58) | MAOBSIGMAR1MAOAMAPTRXFP1 | |
| SCHEMBL8498459 | 0.72 | SIGMAR1 (0.58) | MAOBSIGMAR1MAOAMAPTRXFP1 | |
| SCHEMBL38729 | 0.72 | SIGMAR1 (0.58) | MAOBSIGMAR1MAOAMAPTRXFP1 | |
| SCHEMBL142556 | 0.72 | SIGMAR1 (0.58) | MAOBSIGMAR1MAOAMAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089373-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008044667-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | WO | disclosed |